Human blood plasma as source for biotherapeutics is very limited and safety concerns still persist, leading to a growing need for recombinant plasma proteins. In addition, glycosylation patterns of most plasma proteins are very complex and represent a huge challenge to recombinant protein expression. With a comprehensive portfolio of glyco-optimized human cell lines, the CAP-Go expression system paves the way for recombinant plasma proteins.
Recombinant human C1 Inhibitor (C1-INH)
C1-Inhibitor deficiency patients suffer from an inherited form of angioedema that are currently predominantly being treated with intravenous injections of C1 Inhibitor purified from human serum. CEVEC´s CAP-Go derived C1 Inhibitor showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. This result, in combination with excellent specific activities of CAP-Go derived C1 Inh and commercially attractive production yields, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications. CEVEC plans to partner the further preclinical & clinical development of the molecule. For further information contact email@example.com or give us a call under +49 221 46020800.